UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) is a dopamine agonist. In a double blind test, the product improved patients' ability to do routine daily tasks and their motor function scores compared to placebo. UCB expects to file for China approval this year; NEUPRO is already sold in the US, Europe and Japan.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
